145 related articles for article (PubMed ID: 10927020)
1. Role of NADPH:cytochrome P450 reductase in the hypoxic accumulation and metabolism of BRU59-21, a technetium-99m-nitroimidazole for imaging tumor hypoxia.
Melo T; Ballinger JR; Rauth AM
Biochem Pharmacol; 2000 Sep; 60(5):625-34. PubMed ID: 10927020
[TBL] [Abstract][Full Text] [Related]
2. Cellular accumulation and retention of the technetium-99m-labelled hypoxia markers BRU59-21 and butylene amine oxime.
Zhang X; Melo T; Rauth AM; Ballinger JR
Nucl Med Biol; 2001 Nov; 28(8):949-57. PubMed ID: 11711315
[TBL] [Abstract][Full Text] [Related]
3. Flux through multicellular layers of a technetium-99m-nitroimidazole for imaging hypoxia.
Melo T; Tunggal JK; Ballinger JR; Rauth AM
Cancer Biother Radiopharm; 2002 Oct; 17(5):515-26. PubMed ID: 12470421
[TBL] [Abstract][Full Text] [Related]
4. BRU59-21, a second-generation 99mTc-labeled 2-nitroimidazole for imaging hypoxia in tumors.
Melo T; Duncan J; Ballinger JR; Rauth AM
J Nucl Med; 2000 Jan; 41(1):169-76. PubMed ID: 10647620
[TBL] [Abstract][Full Text] [Related]
5. Modifying the in vitro accumulation of BMS181321, a technetium-99m-nitroimidazole, with unlabelled nitroaromatics.
Melo T; Hua HA; Ballinger JR; Rauth AM
Biochem Pharmacol; 1997 Sep; 54(6):685-93. PubMed ID: 9310345
[TBL] [Abstract][Full Text] [Related]
6. Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C1.
Keyes SR; Fracasso PM; Heimbrook DC; Rockwell S; Sligar SG; Sartorelli AC
Cancer Res; 1984 Dec; 44(12 Pt 1):5638-43. PubMed ID: 6437671
[TBL] [Abstract][Full Text] [Related]
7. Effect of a second nitroimidazole redox centre on the accumulation of a hypoxia marker: synthesis and in vitro evaluation of 99mTc-labeled bisnitroimidazole propylene amine oxime complexes.
Huang H; Zhou H; Li Z; Wang X; Chu T
Bioorg Med Chem Lett; 2012 Jan; 22(1):172-7. PubMed ID: 22153341
[TBL] [Abstract][Full Text] [Related]
8. High levels of recombinant CYP3A4 expression in Chinese hamster ovary cells are modulated by coexpressed human P450 reductase and hemin supplementation.
Ding S; Yao D; Burchell B; Wolf CR; Friedberg T
Arch Biochem Biophys; 1997 Dec; 348(2):403-10. PubMed ID: 9434754
[TBL] [Abstract][Full Text] [Related]
9. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy.
Jounaidi Y; Waxman DJ
Cancer Res; 2000 Jul; 60(14):3761-9. PubMed ID: 10919648
[TBL] [Abstract][Full Text] [Related]
10. Requirements for cytochrome b5 in the oxidation of 7-ethoxycoumarin, chlorzoxazone, aniline, and N-nitrosodimethylamine by recombinant cytochrome P450 2E1 and by human liver microsomes.
Yamazaki H; Nakano M; Gillam EM; Bell LC; Guengerich FP; Shimada T
Biochem Pharmacol; 1996 Jul; 52(2):301-9. PubMed ID: 8694855
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia.
Ballinger JR; Kee JW; Rauth AM
J Nucl Med; 1996 Jun; 37(6):1023-31. PubMed ID: 8683295
[TBL] [Abstract][Full Text] [Related]
12. Improving tumor/muscle and tumor/blood ratios of
Li S; Chu T
Bioorg Med Chem Lett; 2023 Feb; 82():129154. PubMed ID: 36736496
[TBL] [Abstract][Full Text] [Related]
13. Targeting hypoxia in tumors using 2-nitroimidazoles with peptidic chelators for technetium-99m: effect of lipophilicity.
Zhang X; Su ZF; Ballinger JR; Rauth AM; Pollak A; Thornback JR
Bioconjug Chem; 2000; 11(3):401-7. PubMed ID: 10821657
[TBL] [Abstract][Full Text] [Related]
14. TcO(PnA.O-1-(2-nitroimidazole)) [BMS-181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: synthesis, characterization, and xanthine oxidase-catalyzed reduction.
Linder KE; Chan YW; Cyr JE; Malley MF; Nowotnik DP; Nunn AD
J Med Chem; 1994 Jan; 37(1):9-17. PubMed ID: 8289205
[TBL] [Abstract][Full Text] [Related]
15. Reductive metabolism of the nitroimidazole-based hypoxia-selective cytotoxin NLCQ-1 (NSC 709257).
Papadopoulou MV; Ji M; Rao MK; Bloomer WD
Oncol Res; 2003; 14(1):21-9. PubMed ID: 14552588
[TBL] [Abstract][Full Text] [Related]
16. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine: an anticancer agent targeting hypoxic cells.
Seow HA; Penketh PG; Shyam K; Rockwell S; Sartorelli AC
Proc Natl Acad Sci U S A; 2005 Jun; 102(26):9282-7. PubMed ID: 15964988
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and bioevaluation of the cyclopentadienyl tricarbonyl technetium-99m 2-nitroimidazole derivatives for tumor hypoxia imaging.
Su H; Chu T
Bioorg Med Chem Lett; 2022 Mar; 60():128583. PubMed ID: 35085720
[TBL] [Abstract][Full Text] [Related]
18. One-electron reductive bioactivation of 2,3,5,6-tetramethylbenzoquinone by cytochrome P450.
Goeptar AR; te Koppele JM; van Maanen JM; Zoetemelk CE; Vermeulen NP
Biochem Pharmacol; 1992 Jan; 43(2):343-52. PubMed ID: 1310854
[TBL] [Abstract][Full Text] [Related]
19. Biochemical characterization of rat P450 2C11 fused to rat or bacterial NADPH-P450 reductase domains.
Helvig C; Capdevila JH
Biochemistry; 2000 May; 39(17):5196-205. PubMed ID: 10819987
[TBL] [Abstract][Full Text] [Related]
20. Distinct roles of cytochrome P450 reductase in mitomycin C redox cycling and cytotoxicity.
Wang Y; Gray JP; Mishin V; Heck DE; Laskin DL; Laskin JD
Mol Cancer Ther; 2010 Jun; 9(6):1852-63. PubMed ID: 20501808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
